Could a specific protein's expression level predict outcomes in HER2-positive breast cancer? This study investigates the role of SLC35A2 in breast cancer, an area with limited existing research. Immunohistochemical analysis reveals that SLC35A2 is significantly overexpressed in breast cancer tissues compared to non-neoplastic tissues, with its expression independently correlated with HER2 positivity. Survival analysis indicates that low SLC35A2 expression is associated with a more favorable prognosis in HER2-positive breast cancer. These findings suggest that SLC35A2 may serve as a potential prognostic marker, offering insights into improved long-term outcomes for HER2-positive breast cancer patients with decreased SLC35A2 levels.
Published in Discover Oncology, this research aligns with the journal's focus on advancing the understanding and treatment of cancer. By exploring the role of SLC35A2 and its association with HER2 positivity in breast cancer, this study contributes to the identification of potential prognostic markers and therapeutic targets.